4

PRIMARY DOCUMENT

Company: Ultragenyx Pharmaceutical Inc.
Filed: May 20, 2015
Period of Report: May 18, 2015
Accession Number: 0001562180-15-000386

View Document ↗ View on SEC.gov ↗